Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 3
1965 1
1967 2
1969 3
1970 3
1971 8
1972 6
1973 6
1974 7
1975 3
1976 3
1977 3
1978 1
1979 1
1980 6
1981 5
1982 5
1983 6
1984 6
1985 2
1986 6
1987 4
1988 7
1989 5
1990 7
1991 7
1992 4
1993 4
1994 4
1995 4
1996 8
1997 6
1998 3
1999 2
2000 3
2001 4
2002 4
2003 5
2004 5
2005 8
2006 13
2007 6
2008 7
2009 12
2010 17
2011 18
2012 11
2013 16
2014 10
2015 22
2016 14
2017 14
2018 6
2019 7
2020 11
2021 10
2022 11
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

368 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for faber d
Search for Fabec D instead (1 results)
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Monés J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ; GATHER2 trial investigators. Khanani AM, et al. Lancet. 2023 Oct 21;402(10411):1449-1458. doi: 10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8. Lancet. 2023. PMID: 37696275
Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.
Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, Abraham P, Fein JG, Chu KW, Clark WL, Leal S, Schmelter T, Hirshberg B, Yancopoulos GD, Vitti R; CANDELA Study Investigators. Wykoff CC, et al. JAMA Ophthalmol. 2023 Sep 1;141(9):834-842. doi: 10.1001/jamaophthalmol.2023.2421. JAMA Ophthalmol. 2023. PMID: 37535382
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. Khanani AM, et al. Ophthalmology. 2024 Feb 19:S0161-6420(24)00134-9. doi: 10.1016/j.ophtha.2024.02.014. Online ahead of print. Ophthalmology. 2024. PMID: 38382813 Free article.
Single fiber reflectance spectroscopy calibration.
Zhang XU, Post AL, Faber DJ, van Leeuwen TG, Sterenborg HJCM. Zhang XU, et al. Among authors: faber dj. J Biomed Opt. 2017 Oct;22(10):1-4. doi: 10.1117/1.JBO.22.10.100502. J Biomed Opt. 2017. PMID: 29086543 Free article.
Agro-economic impact of cattle cloning.
Faber DC, Ferre LB, Metzger J, Robl JM, Kasinathan P. Faber DC, et al. Cloning Stem Cells. 2004;6(2):198-207. doi: 10.1089/1536230041372463. Cloning Stem Cells. 2004. PMID: 15268796 Review.
Commercialization of animal biotechnology.
Faber DC, Molina JA, Ohlrichs CL, Vander Zwaag DF, Ferré LB. Faber DC, et al. Theriogenology. 2003 Jan 1;59(1):125-38. doi: 10.1016/s0093-691x(02)01264-5. Theriogenology. 2003. PMID: 12499024 Review.
368 results